Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
EL

NYSE · ELAN

Elanco Animal Health Incorporated

Healthcare · Drug Manufacturers - Specialty & Generic

$23.06

Down-$0.18 (-0.77%)

Updated Oct 31, 2026, 4:03 PM

SID Score

5.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
10.58B
P/E ratio
293.94
Dividend yield
0.00%
52-week range
$19.40 – $27.98
Volume
3.45M
Avg. volume
5.48M

Price performance · ELAN

ELAN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ELAN closed at $23.06 after 21 trading sessions, up 4.16% for the selected period.

Last close
$23.06
Period change
+4.16%
Period low
$22.14
Period high
$23.55
Daily close
View OHLC price history
ELAN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$23.48$23.48$22.93$23.063.45M
Oct 29, 2026$22.84$23.25$22.775$23.243.49M
Oct 28, 2026$22.75$22.92$22.56$22.654.39M
Oct 27, 2026$22.91$23.19$22.595$22.654.99M
Oct 26, 2026$22.62$23.095$22.18$22.964.21M
Oct 23, 2026$22.44$22.76$22.31$22.524.28M
Oct 22, 2026$22.43$22.8423$22.35$22.694.45M
Oct 21, 2026$22.975$22.975$22.23$22.554.86M
Oct 20, 2026$23.29$23.47$22.03$22.708.25M
Oct 19, 2026$23.71$23.96$23.45$23.492.9M
Oct 16, 2026$23.87$24.11$23.41$23.555.17M
Oct 15, 2026$22.83$23.79$22.80$23.546.65M
Oct 14, 2026$22.38$22.92$22.2647$22.554.94M
Oct 13, 2026$22.63$22.77$22.22$22.413.35M
Oct 12, 2026$22.88$22.93$22.55$22.564.65M
Oct 9, 2026$22.59$22.975$22.42$22.922.52M
Oct 8, 2026$22.08$22.625$22.00$22.544.57M
Oct 7, 2026$22.26$22.62$22.16$22.364.2M
Oct 6, 2026$22.72$23.04$22.23$22.487.04M
Oct 5, 2026$22.09$22.725$21.72$22.514.79M
Oct 2, 2026$22.04$22.36$21.77$22.145M

Latest ELAN news

The latest Smart Investors Daily articles mentioning ELAN.

Stock researchCompany · Overview

ELAN research

Overview

Company profile and research snapshot.

Company profile

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$24.75
Implied upside
—
Analysts
—
ELAN recent ratings
DateFirmRatingTarget
Oct 29, 2026Morgan StanleyEqual-Weight—
Oct 20, 2026JefferiesHold—
Oct 16, 2026Goldman SachsBuy—
Aug 6, 2026KeybancOverweight—
Aug 6, 2026UBSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Elanco Animal Health Appoints Jamie Preston as Chief People Officer

Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Jamie Preston as Executive Vice President and Chief People Officer, effective November 3rd. Preston's appointment follows an extensive and competitive search as part of the company's commitment to attract, develop and retain an engaged global workforce while embedding inclusion, well-being and purpose into daily operations. Preston succeeds Dave Kinard, who intends to retire at the end of the year. Kinard will work

Yahoo · Oct 22, 2026

Does Elanco Animal Health (ELAN) Sit Below Fair Value After Zenrelia?

Elanco Animal Health has quietly turned into a strong performer over the past few years, which naturally puts today’s share price under the microscope. With the stock now reflecting that track record, the key question is whether the cash it can generate over time supports where the market is pricing it. Over the past 3 years, Elanco Animal Health has delivered a 154.5% return, so a lot of optimism is already embedded in the current valuation case. Zenrelia treating more than 2,000,000 dogs...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By